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doi:10.1016/j.ejvs.2008.08.020Abstract Objectives: To evaluate the long-term results of catheter-directed thromboly-
sis (CDT) and the feasibility of stent placement for lower extremity deep vein thrombosis
(DVT).
Design & methods: Retrospective study of 34 patients (10 men and 24 women, mean age
55, S.D. 13 years) with lower extremity DVT underwent CDT at Seoul National University
Hospital from January 1999 to October 2003. Patient characteristics, risk factors of
DVT, extent of thrombosis, and short-term and long-term results of CDT and/or stent
placement were analysed.
Results: Mean follow-up times were 47 S.D. 16 months. The primary technical success
rate was 97% (complete lysis 68%, partial 29%). During the follow-up periods 11 (32%)
patients showed re-thrombosis. Sixteen (47%) of 34 patients showed chronic change of
vessels during the follow-up periods. By Cox Proportional Hazard analysis, extent of
thrombolysis was a statistically significant factor affecting the freedom of re-thrombosis
and chronic change (PZ 0.008 and PZ 0.001).. Nine (44%) of 21 deployed stents were
obstructed, and the overall stent patency at 3 years was 56.7%. The only factor affecting
the stent patency was stent length more than 6 cm (PZ 0.002, HR 13, 95% CI 2.7e59).2072 2991; fax: þ82 2 766 3975.
r (J. Ha).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
726 Y.J. Park et al.Conclusion: Long-term results of CDT are not satisfactory because of the high recurrence
rate of DVT and it cannot prevent chronic post-thrombotic damage to the affected vessels
despite long-term anticoagulation therapy. Careful long-term surveillance of the venous
function is highly recommended after CDT.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights
reserved.Table 1 Location of thrombus and mean clot burden
reduction
Segments No. (%) Pre-CDTa Post-CDTa P-value
Vena cava 6 (17.7) 0.24 0.00 0.02
Iliac 31 (91.2) 2.53 0.29 0.00
Common femoral 29 (85.3) 2.50 0.24 0.00
Femoral 29 (85.3) 2.15 0.21 0.00
Popliteal 25 (73.5) 1.76 0.18 0.00
Calf 23 (67.6) 1.24 0.21 0.00
a All values listed above are the mean clot burden score for
each vessel segment, pre- and post-CDT. Criteria for scoring
segments with modification of SVS Scoring System: 0Z patent;
1Z subsegmental, nonocclusive thrombus; 2Z subsegmental,
occlusive thrombus; 3Z occlusive thrombus, throughout length
of segment.Introduction
Deep vein thrombosis (DVT) of lower extremity can lead to
pulmonary embolism (PE) in the short term and post-
thrombotic syndrome in the long term.1,2 Although the
conventional treatment of acute DVT is systemic anti-
coagulation (heparinisation followed by oral anti-
coagulation with warfarin) to prevent PE and recurrent
DVT, this form of therapy does not protect the patient from
post-thrombotic syndrome, which can appear months to
years after the acute episode of DVT. In addition, the
results have been largely inadequate in terms of rapid
resolution of symptoms, re-canalisation of long-segment
venous occlusions, and long-term disability from chronic
venous insufficiency.
Early thrombus removal is a logical approach to
improve the long-term outcome of iliofemoral DVT.
Treatment strategies include systemic thrombolytic
therapy, surgical thrombectomy, and catheter-directed
thrombolysis (CDT) with or without stent placement.3e5
CDT allows a higher concentration of the thrombolytic
drug to be introduced directly into the clot. Regional
thrombolysis results in more rapid dissolution of the
thrombus and reduced haemorrhagic complications
compared with systemic infusion.6
Although the short-term results of CDT for lower
extremity DVT have been favourable, there are few reports
regarding the long-term benefits. The aim of this study is to
evaluate the long-term results of CDT and the feasibility of
stent placement for lower extremity DVT.
Materials and Methods
Patients
Medical records of all patients who underwent catheter-
directed thrombolysis (CDT) and/or stent placement for
lower extremity DVT were reviewed. Between January
1999 and October 2003, 34 consecutive patients with 35
symptomatic limbs were identified. All patients under-
went duplex scan and/or computed venography for
diagnosis, treatment, and follow-up for a mean of 47
S.D. 16 months.
The patients included 10 male and 24 female
patients, with a mean age of 55 S.D. 13 years. Acute
(14 days) DVT was treated in 30 limbs and chronic
(>28 days) DVT in 2 patients (mean duration, 9 S.D.
17 days; median, 3.5 days; range, 1e90 days). The
treated extremity was on the left side in 26 of 35 limbs
(74%), on the right in 7 (20%), and both in one patient
(3%). One patient had lower extremity DVT in bothlimbs, but CDT was performed on the left side at acute
onset. All patients had iliofemoral DVT with or without
distal involvement, and extension to distal inferior vena
cava (IVC) was found in 6 cases (Table 1). The risk
factors of DVT were MayeThurner syndrome in 14 (41%)
of 34 patients, hypercoagulability in 11, immobilisation
in 3, vascular compression by intra-abdominal mass in 3,
vascular injury in 3, and unknown origin chronic stenosis
of common iliac vein in 4. No patient had previous
history of DVT or oral contraceptive pill medication.
Procedures
The institutional review board approved this retrospective
investigation, and informed consent was obtained from
each patient after a discussion of the risks and benefits of
use of urokinase for CDT, the surgical treatment alterna-
tives including thrombectomy, and the standard medical
therapy.
Vascular access into the affected limb was achieved
through ultrasound (US)-guided entry into the ipsilateral
popliteal vein in all cases. A 6-F vascular sheath was typi-
cally inserted, through which all subsequent catheter and
wire exchanges were performed. Urokinase was the
thrombolytic drug used to treat all cases and infusion was
performed using a multiple-side-hole system. The starting
and ending times of thrombolysis, as well as the concen-
tration and total amount of urokinase administered, were
recorded. All patients received sub-therapeutic heparin
(300e500 U/h) through the vascular sheath during the
procedure. The partial thromboplastin time, haematocrit,
and fibrinogen level were monitored. Prophylactic IVC filter
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thrombus in the vena cava performed.
If residual organised thrombus and/or stenotic segment
was found in follow-up venography, balloon angioplasty
(nZ 27, 79%), aspiration thrombectomy (nZ 4), and self-
expandable Nitinol stent placement (nZ 21, 62%) were
performed. After establishment of venous patency, all the
patients were treated with intravenous hydration,
compression stockings (30e40 mmHg ankle gradient stock-
ings) and were encouraged to ambulate the ward. In addi-
tion, patients were treated with the anticoagulant, heparin
(unfractionated or low molecular weight heparin) and
converted to oral warfarin for a minimum of 6 months
(mean 23 S.D. 17 months, range, 6e72). The target thera-
peutic range for the international normalized ratio (INR)
was 2e3 in most patients. V/Q scan was also performed to
rule out PE in19 patients before CDT, 18 after CDT and 12
before and after CDT.
Technical and clinical success evaluation and
follow-up
The degree of thrombolysis was calculated on the venogram
obtained after completion of treatment, including lysis and
additional adjunctive procedure, but before stent deploy-
ment, used to treat lesions uncovered after thrombolysis.
Using the modified SVS scoring system, clot burden for each
vessel was scored from zero to three.7 In brief, a vessel
score of zero indicated a patent vein. A vessel score of one
indicated a segmental non-occlusive thrombus was present.
A vessel score of two indicated a segmental, occlusive
thrombus was present, and a vessel score of three indicated
an occlusive thrombus in the entire length of the vessel
segment. Each vessel (vena cava, iliac, common femoral,
femoral, popliteal, and calf) was individually scored and
then added together to generate the clot burden for the
entire limb. The clot burden reduction was calculated as
the difference between pre- and post-CDT limb scores,
then divided by the pre-CDT score, and then multiplied by
100%. Minimal or no thrombolysis was defined as grade I,
<50% removal of pre-CDT clot burden, partial thrombolysis
as grade II, 50e95%, and complete lysis as grade III,
95e100% removal.
Technical success was assessed from the final venogram
of each treated limb and was defined as successful resto-
ration of venous patency. Clinical success was assessed in
each treated limb and was defined as the presence of
technical success in conjunction with considerable
improvement in lower extremity swelling and/or pain.8
Computed tomographic venography or duplex scan was
performed at 1, 3, 6 and 12 months after lysis, and then at
12-month intervals to evaluate the patency of the treated
venous segment and/or that of the stent. The earliest date
that any of the six lower extremity vessel segments origi-
nally treated by CDT demonstrated thrombosis was defined
as the re-thrombosis date. Chronic change of vessels was
defined as luminal narrowing or cord-like fibrotic change of
the corresponding vessel segments demonstrated in subse-
quent computed venography. The suspicious patients
among them were submitted to undergo duplex scan for the
confirmation of venous insufficiency. In addition, patients
were evaluated for the clinical occurrence of oedema,pigmentation, development of varices, and ulceration on
the treated limb.
Statistical analysis
All non-parametric values are presented as mean and S.D.
The Chi-square or the Fisher’s exact test for comparison of
categorical variables and Student’s t-test for continuous
variables were used to test statistical significance. The
patency rate of iliofemoral vein and stenting was analysed
by KaplaneMeier method and Cox’s proportional hazards
model. SPSS release 12.0 (SPCC Inc.) was used, and
differences were considered statistically significant at
P < 0.05 (two-tailed).
Results
Degree of thrombolysis
The mean duration of thrombolysis was 28 S.D. 12 h and
mean total amount of urokinase was 2.6 S.D. 1.2 million IU
per treated limb. Pre- and post-CDT clot burden is described
in Table 1. The overall limb score decreased from an
average 10.4, pre-CDT, to an average 1.1, post-CDT. The
mean clot burden reduction was 88% after CDT. Complete
lysis was achieved in 18 (53%) of 34 patients, partial lysis was
achieved in 14 (41%) of 34 patients and the technical success
rate was 97%. There was no difference in the duration of
thrombolysis therapy between complete and partial lysis.
The mean duration was 26 S.D 12 and 29 S.D 13 h in each
group. No response to thrombolysis was observed in one
patient (3%). This patient had chronic DVT and received CDT
for 90 h with balloon dilatation and stent placement that
failed. Therefore she underwent surgical thrombectomy
and patch-angioplasty. The 27-year-old female patient had
the venous anomaly of duplicated popliteal vein (PV) and
had multiple segmental partial thrombosis in CFV, SFV, and
medial side PV. After CDT, there was a small amount of
residual thrombus in CFV; however the treatment with
thrombectomy and patch angioplasty ultimately failed. As
a whole, statistically significant clot burden reduction was
achieved in all six vessel segments (Table 1).
In 21 limbs, adjunctive treatment with metallic stent
placement was necessary to treat stenoses and/or short
residual occlusions that were resistant to lytic treatment;
14 of these procedures were performed in patients with
MayeThurner syndrome. A self-expandable Nitinol stent
was used in all cases; the mean diameter and the length of
the stent were 13 S.D. 1.4 mm and 5.4 S.D. 1.6 cm,
respectively.
Complications
Bleeding complications developed in 2 (6%) of 34 patients.
In both cases, unexpected vaginal bleeding was observed.
One case with minor bleeding was treated successfully with
conservative management, and the other case showed
major bleeding which required transfusion of 6 units of
packed RBC.
V/Q scan showed high or intermediate probability of
pulmonary embolism in 3 of 12 patients before and after
Figure 2 Freedom from chronic change of vessel after CDT.
Sixteen (47%) of 34 patients showed chronic changes of vessels,
and the freedom from chronic change by KaplaneMeier anal-
ysis at 1, 3, and 5 years is 88%, 73%, and 45%, respectively. By
Cox Proportional Hazard analysis, re-thrombosis after CDT
increased the chronic change rate (RR 7.6, CI 2.4e24,
PZ 0.001).
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symptoms or signs of pulmonary embolism, even after the
stent placement in MayeThurner syndrome. No immediate
deaths were reported as a result of CDT.
Clinical follow-up and long-term patency
Long-term clinical follow-up was available for all patients
for a mean duration of 47 S.D. 16 months (median,
45 months, range, 15e85 months) post procedure. Mean
duration of anticoagulation was 23 S.D. 17 months (range,
6e72 months). In the follow-up period, symptomatic
recurrences were detected in 13 of 34 patients. Among
these patients, post-thrombotic syndrome was observed in
7 patients (21%) and re-thrombosis in 11 (32%), including
5 (15%) patients who underwent re-thrombolysis for recur-
rent lesions, but showed partial lysis finally resulting in
chronic post-thrombotic damage and stenosis. Freedom
from re-thrombosis by KaplaneMeier analysis at 1, 2, and
3 years is 74%, 71%, and 67%, respectively. By Cox Propor-
tional Hazard analysis, post-CDT residual thrombosis in iliac
vein increased the re-thrombosis rate (Fig. 1, PZ 0.008,
RR 5.3, CI 1.5e18).
Sixteen (47%) of 34 patients showed chronic changes of
vessels during the mean 42 S.D. 20 month follow-up, and
the freedom from chronic change by KaplaneMeier analysis
at 1, 3, and 5 years is 88%, 73%, and 45%, respectively
(Fig. 3). Among the 18 patients who achieved complete
lysis, 5 patients had recurring DVT and 13 patients did not.
All of the 5 patients experienced chronic changes of vessels
in the end, but only one patient without recurrent DVT
showed a chronic change (PZ 0.001) By Cox ProportionalFigure 1 Freedom from re-thrombosis. Eleven (32%) of 34
patients showed re-thrombosis during follow-up, and the
freedom from re-thrombosis by KaplaneMeier analysis at 1, 2,
and 3 years is 74%, 71%, and 67%, respectively. Residual
thrombus in iliac vein after CDT was risk factor of re-throm-
bosis. By Cox Proportional Hazard analysis, post-CDT residual
thrombosis in iliac vein increased the re-thrombosis rate
(RR 5.3, CI 1.5e18, PZ 0.008).Hazard analysis, re-thrombosis increased the chronic
change rate (Fig. 2, PZ 0.001, RR 7.6, CI 2.4e24).
Regarding stent placement in the long term, freedom
from re-thrombosis or chronic change was likely to be
lower in the stent group than in the no-stent group, but
this not statistically significant. Nine (44%) of 21 deployed
stents were obstructed within the mean 31 S.D. 22 monthFigure 3 The patency of stent. Nine (43.8%) of 21 deployed
stents were obstructed, and the overall stent patency at
3 years was 57%. In multivariate analysis, the only factor
affecting the stent patency was stent length more than 6 cm
(PZ 0.002, HR 13, 95% CI 2.7e59).
Table 2 Factors affecting the stent patency (univariate
analysis, nZ 21)
Variables Criteria P-value
Age (years old) 40 vs. >40 NS
Gender NS
Age of thrombus (days) 14 vs. >14 NS
Hypercoagulability NS
Extent of thrombus Involvement below
femoral artery
NS
Degree of thrombolysis Complete vs. partial 0.008
Stent length (cm) 6 vs. >6 0.008*
Re-thrombolysis 0.008
*In multivariate analysis, PZ 0.002 (RR 13, 95% CI 2.7e59).
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57%. Among the risk factors for stent obstruction shown in
Table 2, residual thrombosis, stent length more than 6 cm,
and re-lysis were significant statistically. In multivariate
analysis, the only factor affecting the stent patency was
stent length more than 6 cm (Fig. 3, PZ 0.002, HR 13, 95%
CI 2.7e59).
Two patients died during the follow-up period of more
than 2 years; the causes of death were not directly related
to CDT procedures or complications (advanced gastric
cancer and hepatocellular carcinoma), but these patients
were included in the statistical analysis.
Discussion
The therapeutic goals for treating patients with acute DVT
include prevention of PE, restoration of unobstructed blood
flow through the thrombosed segment, prevention of
recurrent thrombosis, and preservation of venous valve
function. Successful achievement of these clinical goals will
minimise the morbidity and mortality of PE and will
diminish the sequelae of post-thrombotic syndrome. Up to
two-thirds of patients with iliofemoral DVT will develop
oedema and pain, and 5% will develop ulcers despite
adequate anticoagulation.9,10
Thrombolysis is a potentially attractive form of therapy
because it provides the opportunity for prompt restoration
of venous patency and preservation of venous valve func-
tion. The report by Semba and Dake4 in 1994 provided early
insight into the potential role of catheter-directed throm-
bolytic techniques. By focusing the delivery of higher
concentrations of thrombolytic agents, lysis rates can be
improved, treatment duration can be reduced, and
complications associated with patient exposure to systemic
thrombolytic therapy may be reduced. Furthermore,
defects such as stenosis of the common iliac vein can be
treated by balloon angioplasty with or without the place-
ment of endovascular stents.
The initial technical success rate of CDT is reported to
be as high as 78e95%5,7,11 and our study showed a similar
success rate of 97%. According to many literature reviews,
the primary patency rate of DVT at 1 year after CDT is 50e
95%, which declines for the initial 6e12 months. Even after
12 months, DVT recurrence can be observed, therefore it is
not adequate to evaluate the 1 year patency rate of CDT.5,7Our results showed that the patency rate of DVT was likely
to decline for the initial 24 months after CDT and to be
maintained thereafter. Thus, it would be reasonable to
evaluate the patency rate of CDT a minimum of 24 months
after the procedure.
The known risk factors associated with DVT recurrence
are hypercoagulability, extent and age of thrombosis,
previous history of DVT, malignancy, early withdrawal of
anticoagulation, Behcet’s disease, anatomic abnormality of
lower extremity, and residual thrombus resulting from
incomplete lysis. In our study, 11 of 34 patients showed
laboratory hypercoagulability, including 4 patients with
complex coagulation factor abnormalities, protein C defi-
ciency in 4, protein S deficiency in 7, antithrombin (AT) III
deficiency in 1, and hypoplasminogenaemia in 1. Eight (73%)
of 11 patients with coagulation abnormality experienced
DVT recurrence and/or chronic DVT, and the patency rate
was statistically significantly lowered (PZ 0.03). In patients
with hypercoagulability, intravenous heparinisation and
prolonged anticoagulation with warfarin is mandatory in
cases of trauma or surgery, but delivery increases the risk of
thrombosis.12 In addition, they tend to experience DVT
before the age of 40 years, so DVT developed at a young age
requires thorough evaluation for hypercoagulability and
should be treated with prolonged anticoagulation therapy.
Similar to other reports, other significant risk factors of DVT
recurrence included initial incomplete thrombolysis
(PZ 0.030) and extent of DVT (PZ 0.026). However, in
a Cox Proportional Hazard analysis, residual thrombosis in
iliac vein after CDT was the only risk factor increasing the
likelihood of re-thrombosis (PZ 0.008).
After thrombolysis, the degree of lysis was a significant
predictor of early and continued patency. At 3 years, 75% of
limbs with complete thrombolysis remained patent, as
compared with 30% of limbs with partial lysis (PZ 0.03). In
general, acute DVT was a predictor of a better lysis grade
than chronic DVT, although substantial lysis could be ach-
ieved in patients with chronic iliofemoral DVT. In this study,
the critical time was less than 5 days from onset to inter-
vention, which was a shorter time period than the 14 days
reported previously.11 However, two of three patients
treated more than 14 days from symptom onset showed
long-term patency, and it may be beneficial to try CDT in
these patients. On the basis of these data, CDT should be
offered to patients with acute onset DVT with no previous
history of DVT in whom complete lysis can be anticipated.
In general, adjunctive metallic stent placement after
CDT has a patency rate of 64e95%.11,13 Vedantham et al.,
who reported 93% mid-term stent patency in 15 patients,
suggested that early stent placement would minimise the
dosage and the systemic side effects of thrombolytic drugs
and yield a higher patency rate.5 However, instability of the
metallic stent and no available reports of long-term results
were limitations of their study. In our study of the long-
term results of stent placement after CDT, there was no
difference in the freedom of re-thrombosis nor chronic
change between stent and no-stent groups (PZ 0.643),
possibly due to selection bias. We inserted stents in all
cases of MayeThurner syndrome, in which stent placement
could reduce the risk of DVT recurrence. In patients with
hypercoagulability and venous compression due to intra-
abdominal mass, the beneficial effects of a stent are not
730 Y.J. Park et al.distinct and they do not show statistical significance. Unlike
other reports, as a result of patient selection bias, the stent
placement group was not likely to have a higher patency
rate than the no-stent group.
Our study also revealed the risk factors associated with
the long-term patency of the stent itself, such as incomplete
thrombolysis (PZ 0.008), re-lysis (PZ 0.008) and stent
length longer than 6 cm (PZ 0.008). Among these, long stent
placement was the only significant factor in a multivariate
analysis and we consider that this should be avoided if
possible. Although there have been no other reports about
the effect of stent length on patency after CDT, it is reported
in coronary interventions that a longer stent promotes
platelet activation and increases re-stenosis.14,15
Sixteen of 34 patients developed post-thrombotic scar-
ring of deep veins during the mean 42 month follow-up
period. CDT is effective in early removal of clot burden and
in restoration of venous flow, but cannot prevent subsequent
deterioration of veins. In contrast, chronic change of vessel
showed an initial slow decline, but after 2 years showed
rapid progression despite of prolonged anticoagulation.
Thus, it is suggested that careful long-term surveillance of
the venous function is highly recommended after CDT.
Major bleeding complications were limited to two cases
of vaginal bleeding in this series, which ceased with
conservative management. In addition, although V/Q scan
showed several cases of suspicious PE, there was no episode
of symptomatic PE. Within the limitations of this small-
sized retrospective study, information regarding valvular
dysfunction and post-thrombotic syndrome could not be
collected, suggesting a need for a further prospective study
on a larger scale.
In conclusion, although the initial success rate of CDT
was satisfactory, in long-term follow-up CDT resulted in
a high frequency of recurrent DVT, especially in patients
with residual thrombus after initial lysis, hypercoagula-
bility, and longer extent of thrombus. Adjunctive self-
expandable metallic stents have a beneficial effect in
cases of iliac vein compression, stenosis due to organised
thrombus, and focal obstruction, but a further prospec-
tive well-controlled study is needed to explore the
long-term results. Long-term anticoagulation does not
guarantee the maintenance of long-term patency. Initial
patency was able to be maintained by the help of CDT.
However, it was not effective in prevention of chronic
change of the vessels in almost all cases, and careful
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